{"id":"NCT00177047","sponsor":"Masonic Cancer Center, University of Minnesota","briefTitle":"Autologous Transplant for Multiple Myeloma","officialTitle":"Autologous Transplantation for Multiple Myeloma","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2004-04-20","primaryCompletion":"2020-08-01","completion":"2020-08-01","firstPosted":"2005-09-15","resultsPosted":"2021-11-09","lastUpdate":"2021-11-09"},"enrollment":363,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"PROCEDURE","name":"Stem Cell Transplant","otherNames":["Bone Marrow Transplant"]},{"type":"DRUG","name":"Cyclophosphamide + Mesna","otherNames":["Cytoxan"]},{"type":"DRUG","name":"Melphalan","otherNames":["Alkeran"]},{"type":"BIOLOGICAL","name":"Granulocyte-colony stimulating factor","otherNames":["G-CSF"]}],"arms":[{"label":"Chemotherapy and Transplant Treatment","type":"EXPERIMENTAL"}],"summary":"This is a study of a regimen of melphalan and autologous stem cells for patients with multiple myeloma. We hypothesize that this particular regimen will improve the survival of these patients.","primaryOutcome":{"measure":"Number of Participants Achieving a Complete Response","timeFrame":"100 Days post transplant","effectByArm":[{"arm":"Chemotherapy and Transplant Treatment","deltaMin":51,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":363},"commonTop":["Infection","Pneumonia","Neuropathy","Thrombosis","Tachycardia"]}}